88 citations · 89 across the 4 of their papers we have counts for
4 papers
Anonymising Clinical Data for Secondary Use
Irene Ferreira, Chris Harbron, Alex Hughes +2
Secondary use of data already collected in clinical studies has become more and more popular in recent years, with the commitment of the pharmaceutical industry and many academic i…
The use of external controls: To what extent can it currently be recommended?
Hans Ulrich Burger, Christoph Gerlinger, Chris Harbron +4
With more and better clinical data being captured outside of clinical studies and greater data sharing of clinical studies, external controls may become a more attractive alternati…
Patient-reported outcomes in the context of the benefit assessment in Germany
Sarah Böhme, Christoph Gerlinger, Susanne Huschens +7
Since the 2011 Act on the Reform of the Market for Medicinal Products, benefit dossiers are submitted by pharmaceutical companies to facilitate the Health Technology Assessment (HT…
Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?
Cornelia Ursula Kunz, Silke Jörgens, Frank Bretz +6
Very recently the new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified and the coronavirus disease 2019 (COVID-19) declared a pandemic by the Wo…